Compare Pfizer with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs VENUS REMEDIES - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER VENUS REMEDIES PFIZER/
VENUS REMEDIES
 
P/E (TTM) x 36.5 -1.1 - View Chart
P/BV x 6.2 0.1 8,322.3% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 PFIZER   VENUS REMEDIES
EQUITY SHARE DATA
    PFIZER
Mar-19
VENUS REMEDIES
Mar-18
PFIZER/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs3,840126 3,050.0%   
Low Rs2,08061 3,404.3%   
Sales per share (Unadj.) Rs455.0301.8 150.8%  
Earnings per share (Unadj.) Rs93.8-24.9 -377.1%  
Cash flow per share (Unadj.) Rs109.42.5 4,298.8%  
Dividends per share (Unadj.) Rs22.500-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs658.2293.3 224.4%  
Shares outstanding (eoy) m45.7512.34 370.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.50.3 2,099.9%   
Avg P/E ratio x31.6-3.8 -839.5%  
P/CF ratio (eoy) x27.136.7 73.6%  
Price / Book Value ratio x4.50.3 1,410.6%  
Dividend payout %24.00-   
Avg Mkt Cap Rs m135,4201,154 11,737.0%   
No. of employees `0002.60.9 284.4%   
Total wages/salary Rs m3,238393 823.8%   
Avg. sales/employee Rs Th7,911.44,026.1 196.5%   
Avg. wages/employee Rs Th1,230.9425.0 289.6%   
Avg. net profit/employee Rs Th1,630.7-331.8 -491.5%   
INCOME DATA
Net Sales Rs m20,8153,724 558.9%  
Other income Rs m1,67423 7,439.6%   
Total revenues Rs m22,4893,747 600.2%   
Gross profit Rs m5,712395 1,446.8%  
Depreciation Rs m714338 211.0%   
Interest Rs m73354 20.6%   
Profit before tax Rs m6,599-275 -2,397.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,30932 7,305.7%   
Profit after tax Rs m4,291-307 -1,398.0%  
Gross profit margin %27.410.6 258.9%  
Effective tax rate %35.0-11.5 -304.8%   
Net profit margin %20.6-8.2 -250.1%  
BALANCE SHEET DATA
Current assets Rs m27,1672,638 1,029.9%   
Current liabilities Rs m8,9172,305 386.9%   
Net working cap to sales %87.78.9 980.4%  
Current ratio x3.01.1 266.2%  
Inventory Days Days68135 50.1%  
Debtors Days Days3046 65.0%  
Net fixed assets Rs m8,8624,871 181.9%   
Share capital Rs m458123 370.7%   
"Free" reserves Rs m29,6563,496 848.4%   
Net worth Rs m30,1133,619 832.1%   
Long term debt Rs m251,374 1.8%   
Total assets Rs m39,4007,509 524.7%  
Interest coverage x91.50.2 41,046.2%   
Debt to equity ratio x00.4 0.2%  
Sales to assets ratio x0.50.5 106.5%   
Return on assets %11.10.6 1,754.3%  
Return on equity %14.2-8.5 -168.0%  
Return on capital %22.11.6 1,399.3%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m4280-   
Fx outflow Rs m786517 152.3%   
Net fx Rs m-358-517 69.3%   
CASH FLOW
From Operations Rs m978514 190.1%  
From Investments Rs m351-123 -285.3%  
From Financial Activity Rs m-1,099-387 283.8%  
Net Cashflow Rs m2314 5,495.2%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 0.2 4,166.7%  
FIIs % 4.9 0.6 844.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 66.4 35.7%  
Shareholders   85,207 20,121 423.5%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  FDC LTD.  ASTRAZENECA PHARMA  BIOCON   

Compare PFIZER With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 72 Points Lower; Capital Goods and Auto Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day marginally lower.

Related Views on News

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Nov 18, 2019 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS